Can't help but be turned off my certain aspects of this companyI think they are overpaying for products that are coming off patent in the near term. They target under appreciated products but they are not getting a bargain price.
They have no choice but to issue shares to grow from here, they can't borrow much more.
Executive base salaries seem reasonable but when you add in stock options they start to get too high for my liking.
I feel like the company wants to grow too fast.
I think Biosyent is the stock to be in if you like this space.